Notably, the first FDA-approved biologic was dupilumab (Dupixent; Regeneron, Sanofi), and this approval took place less than 1 year ago in September 2024. Khavandi: Inhaled therapy — viewed as a ...

Dupixent isn’t the first biologic tested in people with COPD. There are six biologics approved for asthma and almost all of them have been studied in COPD, Drummond said.

Dupixent could also face new biologic competition. Nucala, a GSK antibody that blocks the IL-5 pathway, recently posted positive Phase 3 data in a COPD study.

Dupilumab was approved by the FDA to treat bullous pemphigoid, that demonstrated its efficacy in achieving sustained disease ...

Dupixent® (dupilumab) Is the First and Only Biologic to Achieve Significant Improvements in Disease Remission and Symptoms in Bullous Pemphigoid (BP) Positive Pivotal Trial ...

Dupixent is the first and only biologic to achieve significant improvements in disease remission and symptoms in bullous pemphigoid positive pivotal study Study met the primary and all key ...

IL-4 and IL-13 inhibitor Dupixent (dupilumab) is the first biologic drug to show an improvement in remission and symptoms in ...

Adults on dupilumab for severe chronic rhinosinusitis with nasal polyps had better outcomes than those who used omalizumab, ...

Dupixent (dupilumab) is a prescription drug. It’s used to treat chronic (ongoing) rhinosinusitis (nasal and sinus inflammation) due to nasal polyps. Dupixent is a biologic drug and does not come ...

French pharma major Sanofi and US partner Regeneron Pharmaceuticals yesterday presented positive results from the EVEREST Phase IV study of adults with severe chronic rhinosinusitis with nasal polyps ...